Patries M Herst1, Noelle C Bennett2, Annie E Sutherland2, Ruth I Peszynski2, Dean B Paterson3, Marieke L Jasperse4. 1. Department of Radiation Therapy, University of Otago, Wellington, New Zealand. Electronic address: patries.herst@otago.ac.nz. 2. Radiation Oncology Department, Southern Blood and Cancer Centre, Dunedin Hospital, New Zealand. 3. Department of Radiation Therapy, University of Otago, Wellington, New Zealand. 4. Department of Psychological Medicine, University of Otago, Wellington, New Zealand.
Abstract
PURPOSE:Safetac-based soft silicone dressings used in a management setting decrease the severity of radiation-induced acute skin reactions but do not affect moist desquamation rates. Here we investigate the prophylactic use of another Safetac product, Mepitel Film, on moist desquamation rates. MATERIAL AND METHODS: A total of 80 breast cancer patients receiving radiation therapy were recruited between October 2012 and April 2013; 78 participants contributed data for analysis. Lateral and medial halves of the skin areas to be irradiated were randomised to Mepitel Film or aqueous cream; skin dose was measured using thermoluminescent dosimeters; skin reaction severity was assessed using RISRAS and RTOG scales. RESULTS:Overall skin reaction severity was reduced by 92% (p<0.0001) in favour of Mepitel Film (RISRAS). All patients developed some form of reaction in cream-treated skin which progressed to moist desquamation in 26% of patients (RTOG grades I: 28%; IIA: 46%; IIB: 18%; III: 8%). Only 44% of patients had a skin reaction under the Film, which did not progress to moist desquamation in any of the patients (RTOG grades I: 36%; IIA: 8%). CONCLUSIONS: Mepitel Film completely prevented moist desquamation and reduced skin reaction severity by 92% when used prophylactically in our cohort.
RCT Entities:
PURPOSE: Safetac-based soft silicone dressings used in a management setting decrease the severity of radiation-induced acute skin reactions but do not affect moist desquamation rates. Here we investigate the prophylactic use of another Safetac product, Mepitel Film, on moist desquamation rates. MATERIAL AND METHODS: A total of 80 breast cancerpatients receiving radiation therapy were recruited between October 2012 and April 2013; 78 participants contributed data for analysis. Lateral and medial halves of the skin areas to be irradiated were randomised to Mepitel Film or aqueous cream; skin dose was measured using thermoluminescent dosimeters; skin reaction severity was assessed using RISRAS and RTOG scales. RESULTS: Overall skin reaction severity was reduced by 92% (p<0.0001) in favour of Mepitel Film (RISRAS). All patients developed some form of reaction in cream-treated skin which progressed to moist desquamation in 26% of patients (RTOG grades I: 28%; IIA: 46%; IIB: 18%; III: 8%). Only 44% of patients had a skin reaction under the Film, which did not progress to moist desquamation in any of the patients (RTOG grades I: 36%; IIA: 8%). CONCLUSIONS: Mepitel Film completely prevented moist desquamation and reduced skin reaction severity by 92% when used prophylactically in our cohort.
Authors: Lee C L Chin; Elina K Cook; Darren Yohan; Anthony Kim; Carolyn Niu; Brian C Wilson; Stanley K Liu Journal: Biomed Opt Express Date: 2017-02-21 Impact factor: 3.732
Authors: Tara Behroozian; Lauren T Milton; Neil H Shear; Erin McKenzie; Yasmeen Razvi; Irene Karam; Kucy Pon; Henry Lam; Emily Lam; Edward Chow Journal: Support Care Cancer Date: 2020-11-17 Impact factor: 3.603
Authors: Songmi Ahn; Kihoon Sung; Hyun Ju Kim; Young Eun Choi; Young Kyu Lee; Jeong Soo Kim; Seul Ki Lee; Joo-Young Roh Journal: In Vivo Date: 2020 Jan-Feb Impact factor: 2.155